

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-72. (Canceled)

73. (Previously Presented) An isolated polypeptide comprising SEQ ID NO:392.

74. (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue, and wherein said polypeptide is not SEQ ID NO:393.

75. (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

76. (Currently Amended) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, ~~or a sequence having at least 90% identity to said polypeptide,~~ wherein said polypeptide reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392 ~~is over-expressed in ovarian cancer relative to normal ovarian tissue.~~

77. (Currently Amended) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to ~~amino acid residues 1-27 of SEQ ID NO:392,~~ wherein said polypeptide reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392 ~~is over-expressed in ovarian cancer relative to normal ovarian tissue.~~

78. (Previously Presented) A fusion polypeptide comprising a polypeptide according to any one of claims 73-77.

79. (Previously Presented) A composition comprising a polypeptide according to any one of claims 73-77 and at least one physiologically acceptable excipient.

80. (Previously Presented) A composition comprising a polypeptide according to any one of claims 73-77 and at least one adjuvant.

81. (Previously Presented) The composition of claim 80, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.